Gut protein mutations shield against spikes in glucose

November 20, 2018, Brigham and Women's Hospital
Glucose C6H12O6. Credit: Wikipedia.

Why is it that, despite consuming the same number of calories, sodium and sugar, some people face little risk of diabetes or obesity while others are at higher risk? A new study by investigators at Brigham and Women's Hospital has uncovered mutations in a gene that appear to help drive this difference. Individuals with a specific variant in a gene known as SGLT1, which results in reduced uptake of sugars in the gut, had lower incidence of obesity, diabetes, death and heart failure, suggesting that SGLT1 may make a promising therapeutic target for metabolic disease. The team's results were recently published in the Journal of the American College of Cardiology.

"These SGLT1 mutations have not been characterized in the before," said first author Sara Seidelmann, MD, Ph.D., who performed this work as a clinical and research fellow in the Division of Cardiovascular Medicine at the Brigham working with senior author Scott Solomon, MD, professor of Medicine and The Edward D. Frohlich distinguished chair at the Brigham. "We were able to evaluate the association of genetic mutations in SGLT1 with the rise in that occurs in response to dietary in several large populations."

Carbohydrates that enter the body are broken down in the small intestine into smaller pieces, such as glucose, and absorbed into bodily tissues. The sodium/glucose co-transporter-1 (SGLT1) protein plays a critical role in glucose transport into these tissues. Another SGLT family member—SGLT2—is the target of a class of diabetes drugs known as SGLT2 inhibitors. Researchers believe that while SGLT2 inhibitors stop glucose re-uptake in the kidneys, inhibiting SGLT1 could reduce glucose uptake at the source—the —which might reduce the carbohydrate load after a large meal.

Some SGLT1 mutations make the protein dysfunctional, which can cause nutrient malabsorption and even death in newborns, yet other mutations, such as the ones that the BWH researchers found, only slightly alter the protein's function and do not have such devastating outcomes. To examine the effects of the latter kind of mutations, the research team used whole-exome sequencing to identify the unique genetic code of 5,687 participants in the ARIC (Atherosclerosis Risk in Communities) study, an on-going longitudinal analysis o¬¬f participants from four U.S. states. In addition to , these participants had also undergone an oral glucose tolerance test, in which they were provided with a sugary drink and then had their blood glucose levels tested two hours later. The results from the glucose test were then related to genetic variations in SGLT1.

An external validation analysis was performed to study the effect of SGLT1 variants on levels of sugar in the blood after the oral glucose challenge in a large European-Finnish population sample and a replication analysis was performed in African-American participants allowing for heterogenous representation. The researchers also performed a Mendelian randomization analysis to explore the long-term effects of lowering absorption via these on metabolic and cardiovascular disease. This type of analysis enables researchers to estimate the effect of a given variable—post-meal glucose in this case—without conducting an additional study.

Researchers found that 16 percent of European-American participants and 7.5 percent of African-American participants carried an SGLT1 mutation. Those with a mutation were protected from spikes in blood glucose levels after the ingestion of sugars, despite ingesting an equivalent number of calories as others. The Mendelian randomization analysis also showed that these people had a lower risk for obesity and less instances of diabetes mellitus, death and heart failure later in life.

"In addition to confirming the important role of SGLT1 in the digestion of dietary sugars, this work presents new potential opportunities for therapies," said Solomon "The SGLT-1 receptor could be a potential therapeutic target for cardiometabolic disease and suggest that development of drugs that selectively inhibit SGLT-1 could be of benefit in certain high-risk individuals." Nevertheless, Solomon and Seidelmann caution that developing such drugs takes many years and that clinical trials would be needed to determine their safety and efficacy.

Explore further: Gene mutation points to new way to fight diabetes, obesity, heart disease

More information: Sara B. Seidelmann et al, Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk, Journal of the American College of Cardiology (2018). DOI: 10.1016/j.jacc.2018.07.061

Related Stories

Gene mutation points to new way to fight diabetes, obesity, heart disease

October 9, 2018
Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a distinct advantage over those who do not. Those with the mutation have a lower risk ...

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes

September 13, 2017
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.

Lower brain glucose levels found in people with obesity, type 2 diabetes

October 19, 2017
Glucose levels are reduced in the brains of individuals with obesity and type 2 diabetes compared to lean individuals, according to a new Yale study. The finding might explain disordered eating behavior—and even a higher ...

Do you get diabetes from eating too much sugar?

May 24, 2018
There is a widespread belief that sugar is the sole cause of diabetes. After all, the disease is characterised by high levels of sugar in the blood.

Recommended for you

New understanding of mysterious 'hereditary swelling'

December 12, 2018
For the first time ever, biomedical researchers from Aarhus University, Denmark, report cellular defects that lead to a rare disease, hereditary angioedema (HAE), in which patients experience recurrent episodes of swelling ...

Research team traces pathway to cardioprotection in post-ischemic heart failure

December 11, 2018
During an ischemic attack, the heart is temporarily robbed of its blood supply. The aftermath is devastating: reduced heart contractility, heart cell death, and heart failure. Contributing to these detrimental changes is ...

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

Study reveals new link between atrial fibrillation and mutations in heart disease gene

December 11, 2018
Atrial fibrillation (Afib), a heart condition that causes a rapid, irregular heartbeat that increases a person's risk of stroke and heart failure, is fairly common among older adults. However, its early onset form is relatively ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Study: Age, race differences determine risk of stroke in women and men

December 11, 2018
A new study found that, between the ages of 45 and 74 years, white women were less likely to have a stroke than white men, but at age 75 and older, there was no difference in stroke risk between white women and men. In contrast, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.